At least 20 trials are ongoing or planned with at least one all-oral, interferon-free arm. This month, Pharmasset Inc. (NASDAQ:VRUS) announced the start of its Phase III program of PSI-7977, which will consist of three trials combining the nucleotide analog HCV NS5B polymerase inhibitor with ribavirin in various patient subsets. Other regimens combining between one and three experimental compounds, often with and without ribavirin, are in Phase II. (A) Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) markets Incivek telaprevir in the U.S., while Johnson & Johnson (NYSE:JNJ) markets it as Incivo telaprevir in Europe and Mitsubishi Tanabe Pharma Corp.